SecBot SecBot
PRESS-RELEASE ·Filed Jun 29, 2026

BWAY

BrainsWay
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data supports a future FDA submission for PTSD, but no timeline given. Monitor for regulatory updates and peer-reviewed publication. The stock may see near-term momentum on the positive data but lacks a near-term catalyst without a formal FDA submission.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.17
T+0 close · Jun 29, 2026 · via day close
Latest settled
−10.15%
T+60 · $13.63
Vs SPY
−14.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $15.17entry
  2. T+1 · 5mo ago +2.24%α +1.46% · $15.51
  3. T+5 · 4mo ago +5.60%α +4.22% · $16.02
  4. T+20 · 4mo ago +5.27%α +5.55% · $15.97
  5. T+60 · 8w ago −10.15%α −14.54% · $13.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay presented positive real-world data showing 83.5% of comorbid PTSD/MDD patients responded to Deep TMS with a 52% mean symptom reduction. However, the therapy is not yet FDA-cleared for PTSD, limiting immediate commercial impact. The data strengthens the clinical evidence base but does not change near-term revenue or regulatory status.

Key Facts

  • 83.5% of 462 comorbid PTSD/MDD patients responded to Deep TMS (≥50% symptom reduction).
  • Mean PTSD symptom reduction of 52% (PCL-5).
  • 66.6% depression response rate, 27.3% remission rate, mean 50% PHQ-9 reduction.
  • Deep TMS is not yet FDA-cleared for PTSD; results are from a retrospective, real-world study.
  • BrainsWay has three existing FDA clearances: MDD, OCD, and smoking addiction.

Financial Impact

No immediate revenue impact; potential future upside if FDA clearance for PTSD is pursued and obtained.

Risk Factors

  • Deep TMS not FDA-cleared for PTSD; regulatory pathway uncertain.
  • Data is retrospective and subject to peer review; may not replicate in prospective trials.
  • Competing treatments (e.g., other TMS devices, psychotherapy) may limit market adoption.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3318863

US Market Status

Market Closed · Opens Tue (17h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026